A new trading day began on Tuesday, with Cardiff Oncology Inc (NASDAQ: CRDF) stock price up 4.78% from the previous day of trading, before settling in for the closing price of $3.35. CRDF’s price has ranged from $2.01 to $5.64 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 22.80% over the past five years. Meanwhile, its annual earnings per share averaged 13.83%. With a float of $60.75 million, this company’s outstanding shares have now reached $66.53 million.
Let’s look at the performance matrix of the company that is accounted for 33 employees. In terms of profitability, gross margin is 58.04%, operating margin of -10876.83%, and the pretax margin is -10201.67%.
Cardiff Oncology Inc (CRDF) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Cardiff Oncology Inc is 8.68%, while institutional ownership is 42.24%. The most recent insider transaction that took place on Dec 17 ’24, was worth 14,905. In this transaction Chief Financial Officer of this company bought 2,752 shares at a rate of $5.42, taking the stock ownership to the 65,316 shares. Before that another transaction happened on Dec 18 ’24, when Company’s Chief Financial Officer bought 2,400 for $5.00, making the entire transaction worth $12,000. This insider now owns 67,716 shares in total.
Cardiff Oncology Inc (CRDF) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.21 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 13.83% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -8.81% during the next five years compared to 19.36% growth over the previous five years of trading.
Cardiff Oncology Inc (NASDAQ: CRDF) Trading Performance Indicators
Here are Cardiff Oncology Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 6.22. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 395.77.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.93, a number that is poised to hit -0.20 in the next quarter and is forecasted to reach -0.97 in one year’s time.
Technical Analysis of Cardiff Oncology Inc (CRDF)
Cardiff Oncology Inc (NASDAQ: CRDF) saw its 5-day average volume 0.96 million, a negative change from its year-to-date volume of 1.12 million. As of the previous 9 days, the stock’s Stochastic %D was 83.50%. Additionally, its Average True Range was 0.22.
During the past 100 days, Cardiff Oncology Inc’s (CRDF) raw stochastic average was set at 43.73%, which indicates a significant decrease from 90.59% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 47.68% in the past 14 days, which was lower than the 81.14% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.94, while its 200-day Moving Average is $3.20.
